Journal article
Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis
Abstract
BACKGROUND: New direct-acting antiviral agents for hepatitis C genotype 1 infection, boceprevir and telaprevir, offer enhanced sustained virologic response (SVR) among both treatment-naïve and treatment-experienced patients.
AIM: To determine the relative efficacy of the new direct-acting antiviral agents by applying a multiple treatment comparison meta-analysis.
Authors
Cooper C; Lester R; Thorlund K; Druyts E; Khoury ACE; Yaya S; Mills EJ
Journal
QJM, Vol. 106, No. 2, pp. 153–163
Publisher
Oxford University Press (OUP)
Publication Date
February 1, 2013
DOI
10.1093/qjmed/hcs214
ISSN
1460-2725
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Antiviral AgentsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicComparative Effectiveness ResearchDrug Therapy, CombinationFemaleHepacivirusHepatitis C, ChronicHumansInterferon alpha-2Interferon-alphaMaleOligopeptidesPolyethylene GlycolsProlineRandomized Controlled Trials as TopicRecombinant ProteinsRibavirinTreatment Outcome